Objectives: Recent epidemiologic studies have shown an increased mortality from cardiovascular diseases in people with higher serum copper levels. Even though higher serum copper concentration in women using oral contraceptives is well known, there is still uncertainty about the in¯uence of newer progestin compounds in oral contraceptives on serum copper concentration. This issue is of particular interest in the light of recent ®ndings of an increased risk of venous thromboembolism in users of oral contraceptives containing newer progestins like desogestrel compared to users of other oral contraceptives. Design: Cross-sectional epidemiologic study. Examinations included a detailed questionnaire on medical history and lifestyle factors, a seven day food record, and blood samples. Setting: National health and nutrition survey among healthy people living in private homes in West Germany in 1987 ± 1988. Subjects: Nonpregnant and nonlactating women aged 18 ± 44 y (n 610). Results: Overall, the use of oral contraceptives was positively associated with serum copper concentration in by bi-and multivariable linear regression models with log-transformed values of serum copper concentration as dependend variable and oral contraceptive preparations and potential confounding variables as independent variables. Serum copper concentration in women using oral contraceptives varied more strongly by different progestin compounds than by estrogen contents. The highest increase of serum copper was seen in women using oral contraceptives containing antiandrogen progestins (55%; 95% CI: 37 ± 76%), followed by desogestrel (46%; 95% CI: 36 ± 56%), norethisteron/lynestrenol (42%; 95% CI: 29 ± 57%), and levonorgestrel (34%; 95% CI: 24 ± 45%). Conclusion: While elevated serum copper concentration was found in users of all types of oral contraceptives, elevation was more pronounced among women taking oral contraceptives with antiandrogen effective progestins like antiandrogens or third generation oral contraceptives containing desogestrel. Further investigation is required to shed light on the possible role of high serum copper concentration in increasing cardiovascular or thrombotic risk of women using oral contraceptives. Sponsorship: The national health and nutrition survey was funded by the German Ministry of Research and Technology.
Introduction
There is growing evidence that high serum copper concentration is an independent cardiovascular risk factor (Kok et al, 1988; Salonen et al, 1991; Reunanen et al, 1992 Reunanen et al, , 1996 although results are not unequivocal (Klevley et al, 1984; Klevley, 1989) .
The use of oral contraceptives has consistently been found to be associated with an increase of serum copper concentration (Margen & King, 1975; Prasad et al, 1975; Horwitt et al, 1975; Sing et al, 1978; Prema et al, 1980; Crews et al, 1980; Vir & Love, 1981; Hinks et al, 1983; Heese et al, 1987; Stauber & Florence, 1988; Lukaski, 1989; Fischer & L'Abbe, 1990; Johnson et al, 1992; Newhouse et al, 1993; Milne & Johnson, 1993) . However, only few studies have analyzed the in¯uence of different preparations of oral contraceptives on serum copper concentration. The majority of those studies analyzed only ®rst generation oral contraceptives which were introduced in the early 1960s and which contained very high concentrations of estrogens and progestins (Margen & King, 1975) . In the 1970s, second generation drugs were developed which contained reduced doses of estrogens and progestins. Since 1980, third generation oral contraceptives were introduced containing gonadal progestins like desogestrel, gestoden and norgestimate. Little is known about the effect of these new progestins on serum copper concentration.
Taking into consideration that oral contraceptives have been linked to an increase in the incidence of vascular disease (Realini & Goldzieher 1985; La Vecchia, 1991) , the analysis of copper concentration of women using oral contraceptives is important. Recent studies have suggested that the incidence for venous thromboembolism may be even higher in women who use third generation oral contraceptives (WHO, 1995; Jick et al, 1995; Spitzer et al, 1996) compared to women using second generation oral contraceptives, although these results are not homogeneous (Farmer et al, 1997) . The aim of this study was to analyze the in¯uence of different types of oral contraceptives classi®ed by progestin compounds and estrogen contents on serum copper concentration in a population based study from Germany.
Method

Study population
This analysis is based on a national health and nutrition survey among healthy people in Germany conducted in 1987/88 (German Nutrition SurveyÐVERA-StudyÐ Verbundstudie Erna Èhrungserhebung und Risikofaktoren Analytik). A strati®ed random sample was drawn from the non-institutionalized population aged 18 ± 89 years in West-Germany and Berlin. With a participation rate of about 70%, 2006 men and women were recruited in the study. There were only minor differences between the study population and the target population with respect to sex and age distribution (Schneider et al, 1992) . The present analysis on the in¯uence of oral contraceptive use on serum copper concentration was restricted to nonpregnant and nonlactating women aged 18 ± 44 years, who did not take other sex hormones (n 610).
Data collection
Participants were recruited during all seasons and in all regions of West-Germany and Berlin. They completed a detailed questionnaire on medical history and various sociodemographic and lifestyle factors including diet, smoking habits and use of oral contraceptives. In addition, a seven day food record and fasting blood samples were taken. The latter were collected in heparinized tubes between 7 and 10 am. Serum copper was measured with an electrothermic atomic absorption spectrophotometry. A detailed description of the survey methodology has been published elsewhere (Speitling et al, 1992) .
Use of oral contraceptives was categorized into current, past and never use. Information on the use of oral contraceptives was almost complete; only two persons refused to answer the questions about their contraception methods. The name of the currently used oral contraceptive preparation was given by 152 out of 195 women using oral contraceptives (78%). Preparations were classi®ed with regard to progestin compounds according to their chemical structure into: desogestrel, levonorgestrel, lynestrenol/norethisteron, and antiandrogen containing oral contraceptives. The estrogen contents in oral contraceptives was dichotomized in up to 45 mg ethylestradiol (30 ± 45 mg) and equal to 50 mg ethylestradiol. None of the preparations listed by the participants had a higher ethylestradiol content. Three types of preparations contained mestranol rather than ethylestradiol which was converted into the comparable amount of ethylestradiol as described by Murad & Kuret, 1991) .
The following potential confounders were considered in the analysis: Age, smoking status (current smoker/nonsmoker), alcohol consumption (any alcohol consumption, b 0 and 15 g alcohol/d,`15 g alcohol/d) copper intake, history of pregnancies (ever pregnant/never pregnant), and body mass index (BMI). Alcohol consumption and copperintake were calculated from a seven day food record using the data base of the computerized German food-code (BLS: Bundeslebensmittelschlu Èssel). Records were assessed for completeness before coding. The BMI was calculated by dividing the body weight in kilograms by the squared height in metres and was used as measure of relative body weight.
Statistical analysis
In a ®rst step, the study population was described with respect to basic sociodemographic variables. Age, smoking habits, alcohol consumption, nutrient intake, history of pregnancies, and BMI were compared between current, past, and never users of oral contraceptives. The relation of different types of oral contraceptives and covariates (age, smoking, alcohol, copper-intake, history of pregnancies, and BMI) with serum copper concentration was assessed using simple and multiple linear regression with the natural logarithm of serum copper concentration as the dependent variable. The percentage increase of serum copper concentration per unit change in the independent variables was estimated by exponentiating the corresponding regression coef®cients. The log-transformation of serum copper concentration was necessary due to its highly skewed distribution. Copper-intake was likewise log-transformed. We used untransformed values for BMI in all analyses. Forty-®ve out of 610 women were excluded from the multivariable analysis because of missing values in one or more variables. One additional person was excluded because her serum copper concentration exceeded the mean by more than ®ve standard deviations even after log transformation. This woman was therefore regarded as extreme and potentially in¯uential outlier. After this exclusion, the log-transformed values of serum copper concentration were close to normally distributed. Collinearity diagnostics in the multivariable models were performed using the Belsley ± Kuh ± Welsch-criteria (Belsley et al, 1980) . Collinearity was not found to be of concern in these analyses. Table 1 summarizes the bivariate associations of oral contraceptive use with the covariates: 195 women (32.1% of the study population) were current users of oral contraceptives, 322 women (53.0%) had used oral contraceptives in the past, and 91 women (15.0%) were never-users. Current users of oral contraceptives on the average were younger than past and never-users. Forty percent of current users were below age 25 years, compared to 12.1% and Oral contraceptives and copper G Berg et al 28.6% of past and never-users, respectively. Two thirds of current users of oral contraceptives were under 30 years of age. Smoking and alcohol consumption were very common and unrelated to oral contraceptive use in this study population with an overall prevalence of about 50% and 90%, respectively. Examination of copper intake showed no major differences between current, past and never users of oral contraceptives. A history of pregnancies was more frequent in past users of oral contraceptives (74.5%) than in current or never-users (57.7% and 57.2% respectively). The percentage of overweight women (BMI ! 24 kg/m 2 ) was highest in women who had never used oral contraceptives, whereas current users more frequently had a BMI within the recommended range of 19 ± 24 kg/m 2 than other women. Only a minority of women (8.9%) had a BMI below 19 kg/m 2 . One hundred and ®fty-two (77.9%) of the 195 women using oral contraceptives supplied information about their contraceptive medication. Use of different types of oral contraceptives is shown in Table 2 . None of the women reported to take the`minipill' which only contains progestin. About 70% of the women with known oral contraceptive preparations used oral contraceptives containing less than 45 mg ethylestradiol (median dosage during the 21 d of using: 32.4 mg). The most common progestin compound was desogestrel (41%) followed by levonorgestrel (30%) and lynestrenol/norethisteron (19%). Only 16 women (11%) reported to use antiandrogen containing oral contraceptives. There was a variety of combinations of progestin compounds and estrogen contents in this study population. Each combination between categories of progestin compounds and estrogen contents was used. Desogestrel, levonorgestrel and antiandrogen, in contrast to lynestrenol/norethisteron compounds, were more often used with low ethylestradiol concentration. Tables 3 and 4 show the results of bivariate and multiple regression models in which oral contraceptives were classi®ed by progestin compounds and estrogen contents, respectively (the limited sample size did not allow joint classi®cation by both components in a single model). The mean serum copper concentration was higher among users of all types of oral contraceptive preparations than among non-users, but it varied by progestin compounds. The highest copper concentrations were seen in women taking oral contraceptives containing antiandrogens. This was equivalent to an increase of 56% of serum copper concentration compared to non-users of oral contraceptives. Use of oral contraceptives containing desogestrel, lynestrenol/ norethisteron, and levonorgestrel, was associated with an increase of serum copper concentration by 46%, 42%, and 34%, respectively, after adjustment for multiple co-variates. Even compared to women using levonorgestrel containing oral contraceptives, serum copper concentration was signi®cantly higher among women taking antiandrogen containing oral contraceptives (P-value 0.048). Regarding the estrogen content, serum copper concentrations differed only marginally. However, use of oral contraceptives containing lower doses of ethylestradiol was associated with a higher increase of serum copper. In both multiple regression models, a signi®cant positive relationship between BMI and serum copper concentration was observed. The multivariable analyses showed no signi®cant association of age, smoking habits, alcohol consumption, copper intake, and history of pregnancies with serum copper concentration. Overall, the impact of the covariates was small, and adjustment for the covariates had little effect on the estimates of oral contraceptive associated increase of serum copper concentration. In the bi-and multivariable model in which oral contraceptives were classi®ed by progestin compound 28% and 31% of the variance of the natural logarithm of serum copper concentration, respectively, was explained by the predictors. % increase: the increase of log-transformed copper concentration compared to non-users of oral contraceptives (reference) was back-transformed to the natural scale.
Results
c Adjusted for age, smoking, alcohol consumption, copper intake, history of pregnancies, BMI.
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Discussion
This study con®rms the well-known increase in serum copper concentration among oral contraceptive users and suggests that this increase is particularly high in women using oral contraceptives containing antiandrogen effective progestins. The increase also appears to be relatively high among women taking oral contraceptives containing the third generation progestin desogestrel which has a partially antiandrogen capacity (Erkolla et al, 1990) . The differential increase in serum copper concentration by progestin compound is unlikely to be explained by different estrogen contents of the preparations. The impact of oral contraceptives on serum copper concentration has been ascribed to an estrogen-induced release of ceruloplasmin in the liver (O'Leary & Spellacy, 1969; Prema et al, 1980) . Ceruloplasmin is the major transporting protein of serum copper. We found only marginal differences in serum copper concentration, however, comparing users of oral contraceptives with different estrogen contents. The increase of serum copper seemed to be even more pronounced in women using low estrogen dose oral contraceptives ( 45 mg ethylestradiol) than in women using oral contraceptives containing 50 mg ethylestradiol. This might be explained by an opposite effect of progestins in oral contraceptives on serum copper or ceruloplasmin: Levonorgestrel reduces ceruloplasmin in serum and reduces the estrogen effectÐprobably due to its partial androgen activity (Si et al, 1989) whereas desogestrel is more likely to be less androgen or partially antiandrogen (Liukko et al, 1988; Erkolla et al, 1990) . Liukko and colleagues (1988) found that women using desogestrel containing oral contraceptives had a higher increase in serum ceruloplasmin than women using levonorgestrel containing oral contraceptives.
The question whether elevated serum copper concentration in young women using oral contraceptives leads to health risks such as an increased cardiovascular risk cannot be answered with the data at hand. Nevertheless, in cohort studies high serum copper concentration unequivocally was associated with an increased cardiovascular mortality (Kok et al, 1988; Salonen et al, 1991; Reunanen et al, 1992 Reunanen et al, , 1996 . Furthermore, in one of the multinational case control studies about the effect of different progestins in low estrogen oral contraceptives on venous thromboembolic diseases, women who took the most common antiandrogen cyproteronacetat showed a higher thromboembolic riskÐ similar to the third generation progestins, although this ®nding was not signi®cant due to the small numbers (WHO, 1995) . The most used antiandrogen effective oral contraceptive in our analysis was`Diane' which also contains cyproteronacetat. It should be noted, however, that the different impact of various types of oral contraceptives on the risk of cardiovascular diseases may also be mediated by other mechanisms, such as the different impact on lipid metabolisms. The relative importance of different mechanisms by which oral contraceptives may affect cardiovascular diseases requires further research.
Our analysis suggests that sexual hormones are the main predictors for serum copper concentration. In the regression models the different progestin compounds alone explained the largest part (28%) of the total variance of serum copper concentration. By including the different independent covariates in the multivariable analysis the total explained variance of serum copper concentration increased only to 31%. In particular, in the multiple regression models, we observed no signi®cant relationship of age, smoking habits, alcohol consumption, copper intake and history of pregnancies with serum copper concentration. There was a signi®-cant positive association between BMI and serum copper concentration. Adipose tissue is strongly related to sex hormones (Siiteri, 1987) and BMI is closely correlated to adipose tissue (Willett, 1990) . Therefore, the signi®cant association between BMI and serum copper concentration could also be explained by sex hormones. Our ®ndings are in agreement with other studies which also concluded that factors affecting hormonal status (including pregnancies, menopausal status and use of oral contraceptives) are the key determinants of serum copper concentration (Grandejan et al, 1992) .
This study provides a more detailed analysis of the relation of use of different types of oral contraceptives with serum copper concentration than previous studies. Nevertheless, the number of women using the different types of oral contraceptives was limited which led to relative wide con®dence intervals around the estimates of the impact on serum copper. Sample size constraints also hindered analyses of the impact of additional factors, such as duration of oral contraceptive use or the joint assesment of the impact of progestin compounds and estrogen contents. Larger studies are needed to address these aspects in more detail.
Conclusion
Our study suggests that oral contraceptive use, particularly use of antiandrogen effect-ive oral contraceptives, is strongly associated with increased serum copper concentration. Given the increased evidence on the cardiovascular risk associated with high serum copper concentration, the serum copper concentration in women who use oral contraceptives, especially antiandrogen effective oral contraceptives, should not be neglected.
